Tempus AI, Inc. (TEM)
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
- Symbol
- TEM
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Health Information Services
- 52 week range
- 40.77 - 104.32
Valuation
- Share price
- $76.59 (close of 2026-09-23)
- P/E (TTM)
- -53.76x
- Price to book
- 0.03x
- Book value per share
- $2473.00
Price performance
| Period | Change |
|---|
| 1 day | -0.78% |
| 5 days | +9.46% |
| 1 month | +5.37% |
| 3 months | +57.56% |
| 6 months | +55.86% |
| Year to date | +29.70% |
| 1 year | -8.96% |
| All time | +90.29% |
Profitability and growth
- Return on equity
- -49.87%
- Return on invested capital
- -16.58%
- Return on assets
- -10.77%
- Return on capital employed
- -13.29%
- Gross margin
- 51.25%
- Net margin
- -19.27%
- EBITDA margin
- -17.36%
- Revenue growth
- 83.41%
- Net income growth
- 65.28%
- Free cash flow growth
- -13.25%
Cash flow and balance sheet
- Current ratio
- 3.30x
- Net debt to EBITDA
- -9.29x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $1.27B
- Cost of revenue
- $620.00M
- Gross profit
- $651.79M
- EBITDA
- $-220.82M
- Net income
- $-245.03M
- Earnings per share
- $-1.41
- Research and development
- $172.92M
- Shares outstanding
- 174.26K
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2025-12-31 | $1.27B | $651.79M | $-245.03M | $-1.41 |
| 2024-12-31 | $693.40M | $213.59M | $-705.81M | $-6.23 |
| 2023-12-31 | $531.82M | $191.02M | $-214.12M | $-4.20 |
| 2022-12-31 | $320.67M | $51.09M | $-289.81M | $-5.30 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2025-12-31 | 51.25% | -19.27% | -49.87% | -16.58% |
| 2024-12-31 | 30.80% | -101.79% | -1252.79% | -376.65% |
| 2023-12-31 | 35.92% | -40.26% | 15.49% | - |
| 2022-12-31 | 15.93% | -90.38% | 25.67% | - |
Cash and debt by year
| Period end | Cash | Debt |
|---|
| 2025-12-31 | $604.79M | $100.00M |
| 2024-12-31 | $340.95M | - |
| 2023-12-31 | $165.77M | - |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $-239.14M | $124.75M |
| 2024-12-31 | $-211.17M | $534.14M |
| 2023-12-31 | $-248.95M | - |
| 2022-12-31 | $-186.58M | - |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-03
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-07-30 | Jun/2026 | - |
| 2026-05-05 | - | - |
| 2026-02-24 | - | - |
| 2025-11-04 | - | - |
| 2025-08-08 | - | - |
| 2025-05-06 | - | - |
| 2025-02-24 | - | - |
| 2024-11-04 | - | - |
Filings and sources
- Company website
- tempus.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR) · IQVIA Holdings Inc. (IQV)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades